Multi-segmented transdermal dosing unit and methods of use

Abstract

A transdermal dosing unit may include a first segment having a first pharmaceutical in a first reservoir, a first releasing compound, and a first adhesive component, a second segment removably connected to the first segment, the second segment having a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component, and a backing component. The transdermal dosing unit may further include additional segments, and may include a perforated section between each segment. The first adhesive component may have a first adhesion strength, and the second adhesive component may have a second adhesion strength that is either different from or approximately equal to the first adhesion strength. A method of titrating a dose of such a transdermal dosing unit may include applying the transdermal dosing unit to a subject, and removing the first segment while leaving the second segment on the subject.

1 - 26 . (canceled) 
     
     
         27 . A transdermal dosing unit comprising:
 a first segment comprising a first pharmaceutical in a first reservoir, a first releasing component, and a first adhesive component having a first adhesion strength;   a second segment removably connected to the first segment, the second segment comprising a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component having a second adhesion strength different from the first adhesion strength; and   a backing component.   
     
     
         28 . The transdermal dosing unit of  claim 27 , further comprising a third segment removably connected to at least the second segment, the third segment comprising a third pharmaceutical in a third reservoir, a third releasing component, and a third adhesive component having a third adhesion strength different from the first adhesion strength. 
     
     
         29 . The transdermal dosing unit of  claim 27 , further comprising a perforated section between the first segment and the second segment. 
     
     
         30 . The transdermal dosing unit of  claim 27 , wherein the first pharmaceutical and the second pharmaceutical are independently selected from the group consisting of methylphenidate, clonidine, fentanyl, rivastigmine, selegiline, lidocaine, buprenorphine, scopolamine, prednisone, derivatives thereof, and combinations thereof. 
     
     
         31 . The transdermal dosing unit of  claim 27 , wherein the first pharmaceutical comprises methylphenidate in an amount of about 10 mg to about 30 mg. 
     
     
         32 . The transdermal dosing unit of  claim 27 , wherein the first pharmaceutical comprises clonidine in an amount of about 0.1 mg to about 0.6 mg. 
     
     
         33 . The transdermal dosing unit of  claim 27 , wherein the first pharmaceutical comprises fentanyl in an amount of about 12 μg to about 100 μg. 
     
     
         34 . The transdermal dosing unit of  claim 27 , wherein the first pharmaceutical comprises rivastigmine in an amount of about 4.6 mg to about 13.3 mg. 
     
     
         35 . The transdermal dosing unit of  claim 27 , wherein the first pharmaceutical comprises buprenorphine in an amount of about 5 μg to about 20 μg. 
     
     
         36 . The transdermal dosing unit of  claim 31 , wherein the second pharmaceutical comprises selegiline in an amount of about 6 mg to about 12 mg. 
     
     
         37 . The transdermal dosing unit of  claim 33 , wherein the second pharmaceutical comprises lidocaine in a percent concentration from about 1% to about 10%. 
     
     
         38 . The transdermal dosing unit of  claim 35 , wherein the second pharmaceutical comprises lidocaine in a percent concentration from about 1% to about 10%. 
     
     
         39 . The transdermal dosing unit of  claim 35 , wherein the second pharmaceutical comprises clonidine in an amount of about 0.1 mg to about 0.3 mg. 
     
     
         40 . The transdermal dosing unit of  claim 27 , wherein the first pharmaceutical comprises scopolamine in an amount of about 1 mg to about 3 mg. 
     
     
         41 . The transdermal dosing unit of  claim 27 , wherein the first adhesive and the second adhesive are independently selected from the group consisting of an acrylate ester/vinyl pyrrolidone copolymer, a dimethyl silicone polymer, an acrylate polymer, an ethylene vinyl acetate copolymer, a paraffin wax, a low-density polypropylene, a styrene-butadiene copolymer, an ethylene-ethacrylate copolymer, a polyester, a polyamide, a polyurethane, combinations thereof, and derivatives thereof. 
     
     
         42 . The transdermal dosing unit of  claim 27 , wherein an adhesion strength ratio of the first adhesion strength to the second adhesion strength is from about 0.1 to about 0.9. 
     
     
         43 . The transdermal dosing unit of  claim 27 , wherein an adhesion strength ratio of the first adhesion strength to the second adhesion strength is from about 1.1 to about 3.0. 
     
     
         44 . A method of titrating a dose of a transdermal dosing unit, the method comprising:
 applying to a subject a transdermal dosing unit comprising:
 a first segment comprising a first pharmaceutical in a first reservoir, a first releasing component, and a first adhesive component comprising a first adhesion strength; 
 a second segment removably connected to the first segment, the second segment comprising a second pharmaceutical in a second reservoir, a second releasing component, and a second adhesive component comprising a second adhesion strength different from the first adhesion strength; and 
 a backing component 
   removing the first segment while leaving the second segment on the subject.   
     
     
         45 . The method of  claim 44 , wherein an adhesion strength ratio of the first adhesion strength to the second adhesion strength is from about 0.1 to about 0.9. 
     
     
         46 . The method of  claim 44 , wherein an adhesion strength ratio of the first adhesion strength to the second adhesion strength is from about 1.1 to about 3.0.